Skip to main content

Generic Vasostrict Availability

Last updated on Nov 8, 2022.

Vasostrict is a brand name of vasopressin, approved by the FDA in the following formulation(s):

VASOSTRICT (vasopressin - solution;intravenous)

  • Manufacturer: PAR STERILE PRODUCTS
    Approval date: April 17, 2014
    Strength(s): 20UNITS/ML (20UNITS/ML) [RLD] [AP]
  • Manufacturer: PAR STERILE PRODUCTS
    Approval date: December 17, 2016
    Strength(s): 200UNITS/10ML (20UNITS/ML) [RLD]
  • Manufacturer: PAR STERILE PRODUCTS
    Approval date: April 15, 2020
    Strength(s): 40UNITS/100ML (0.4UNITS/ML) [RLD], 60UNITS/100ML (0.6UNITS/ML) [RLD]
  • Manufacturer: PAR STERILE PRODUCTS
    Approval date: April 21, 2021
    Strength(s): 20UNITS/100ML (0.2UNITS/ML) [RLD]

Has a generic version of Vasostrict been approved?

A generic version of Vasostrict has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Vasostrict and have been approved by the FDA:

vasopressin solution;intravenous

  • Manufacturer: AMNEAL
    Approval date: August 5, 2022
    Strength(s): 20UNITS/ML (20UNITS/ML) [AP]
  • Manufacturer: AMPHASTAR PHARMS INC
    Approval date: July 18, 2022
    Strength(s): 20UNITS/ML (20UNITS/ML) [AP]
  • Manufacturer: EAGLE PHARMS
    Approval date: December 15, 2021
    Strength(s): 20UNITS/ML (20UNITS/ML) [AP]
  • Manufacturer: EUGIA PHARMA
    Approval date: August 15, 2022
    Strength(s): 20UNITS/ML (20UNITS/ML) [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vasostrict. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Vasopressin formulations for use in treatment of hypotension
    Patent 10,010,575
    Issued: July 3, 2018
    Assignee(s): Par Pharmaceutical, Inc.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Patent use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
  • Vasopressin formulations for use in treatment of hypotension
    Patent 9,375,478
    Issued: June 28, 2016
    Assignee(s): PAR PHARMACEUTICAL, INC.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Patent use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
  • Vasopressin formulations for use in treatment of hypotension
    Patent 9,687,526
    Issued: June 27, 2017
    Assignee(s): PAR PHARMACEUTICAL, INC.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Patent use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
  • Vasopressin formulations for use in treatment of hypotension
    Patent 9,744,209
    Issued: August 29, 2017
    Assignee(s): PAR PHARMACEUTICAL, INC.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Patent use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
  • Vasopressin formulations for use in treatment of hypotension
    Patent 9,744,239
    Issued: August 29, 2017
    Assignee(s): PAR PHARMACEUTICAL, INC.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Patent use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
  • Vasopressin formulations for use in treatment of hypotension
    Patent 9,750,785
    Issued: September 5, 2017
    Assignee(s): PAR PHARMACEUTICAL, INC.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Drug product
  • Vasopressin formulations for use in treatment of hypotension
    Patent 9,919,026
    Issued: March 20, 2018
    Assignee(s): PAR PHARMACEUTICAL, INC.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Drug product
  • Vasopressin formulations for use in treatment of hypotension
    Patent 9,925,233
    Issued: March 27, 2018
    Assignee(s): PAR PHARMACEUTICAL, INC.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Patent use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
  • Vasopressin formulations for use in treatment of hypotension
    Patent 9,925,234
    Issued: March 27, 2018
    Assignee(s): PAR PHARMACEUTICAL, INC.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Patent use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
  • Vasopressin formulations for use in treatment of hypotension
    Patent 9,937,223
    Issued: April 10, 2018
    Assignee(s): PAR PHARMACEUTICAL, INC.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Patent use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
  • Vasopressin formulations for use in treatment of hypotension
    Patent 9,962,422
    Issued: May 8, 2018
    Assignee(s): PAR PHARMACEUTICAL, INC.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Patent use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
  • Vasopressin formulations for use in treatment of hypotension
    Patent 9,968,649
    Issued: May 15, 2018
    Assignee(s): Par Pharmaceutical, Inc.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Patent use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
  • Vasopressin formulations for use in treatment of hypotension
    Patent 9,974,827
    Issued: May 22, 2018
    Assignee(s): Par Pharmaceutical, Inc.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Patent use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
  • Vasopressin formulations for use in treatment of hypotension
    Patent 9,981,006
    Issued: May 29, 2018
    Assignee(s): PAR PHARMACEUTICAL, INC.

    Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Patent use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.